News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
Bavarian Nordic's VIMKUNYA Chikungunya Vaccine Receives First Swiss Approval from Swissmedic
Bavarian Nordic receives Swissmedic approval for VIMKUNYA, the first chikungunya vaccine approved in Switzerland for individuals 12 years and older.
Seragon's SRN-901 Longevity Drug Shows Significant Lifespan Extension in Preclinical Study
Seragon Biosciences' SRN-901 demonstrated significant lifespan and healthspan extension in mice, marking a breakthrough in longevity therapeutics development.
Boehringer Ingelheim and Zai Lab Launch Phase Ib/II Trial for DLL3-Targeting Combination Therapy in Small Cell Lung Cancer
Boehringer Ingelheim partners with Zai Lab to test obrixtamig plus zocilurtatug pelitecan combination in Phase Ib/II trial for SCLC and neuroendocrine carcinomas.
IMVT-1402 and 7 Other Late-Stage Drugs Transform Generalized Myasthenia Gravis Treatment Pipeline in 2026
Eight promising late-stage drugs including IMVT-1402 from Immunovant signal breakthrough era for generalized myasthenia gravis patients with novel mechanisms.
Drug Development Services Market Surges to $31.5 Billion in 2026, Driven by Pharmaceutical R&D Investments
Drug development services market grows 12.2% CAGR to reach $31.5 billion in 2026, fueled by increased pharmaceutical R&D spending and outsourcing trends.
Medicenna's Bizaxofusp Shows Promise in Brain Cancer Trials Ahead of 2026 Investor Conference
Medicenna's bizaxofusp demonstrates clinical progress in glioblastoma trials with FDA FastTrack status, positioning for major investor presentation in 2026.
Vitestro's Autonomous Robotic Phlebotomy Device Shows Promising Results in Multicenter Clinical Trial
Vitestro publishes peer-reviewed multicenter ADOPT trial results for Aletta® Autonomous Robotic Phlebotomy Device, demonstrating safety and performance.
Grace Therapeutics GTx-104 Phase 3 STRIVE-ON Trial Results Accepted for AAN 2026 Presentation
Grace Therapeutics announces STRIVE-ON Phase 3 safety trial results for GTx-104 injectable nimodipine accepted for AAN 2026 presentation.
MENA Medical Device Regulatory Training Course Launches May 2026 to Address Growing Market Demand
New MENA medical device regulatory training course scheduled for May 18-19, 2026, helps companies navigate approval processes in growing Middle East markets.
CMO/CDMO Market to Reach $5.46 Billion by 2035 as Biologics Manufacturing Outsourcing Accelerates
The global CMO/CDMO market will grow from $4.02 billion to $5.46 billion by 2035, driven by biologics outsourcing and specialized manufacturing demand.
New Clinical Trial Monitoring Course Addresses Rising GCP Compliance Issues in Biopharmaceutical Industry
Online GCP compliance course launches June 2026 to address increasing regulatory inspection findings in clinical trial monitoring across biopharma and CROs.
New GCP Inspections Training Course Addresses ICH GCP E6(R3) and EU CTR Compliance for Pharmaceutical Companies
ResearchAndMarkets.com announces comprehensive GCP inspections training covering EU, FDA, and MHRA expectations under updated ICH GCP E6(R3) guidelines.
Vabysmo Market Report 2026: Roche's Eye Drug Shows Strong Growth Through 2035 Amid Rising Retinal Disorder Cases
New market research reveals Vabysmo's projected growth through 2035, driven by advances in retinal disorder diagnosis and expanding ophthalmology clinics.
GlycoNex GNX1021 Gets PMDA Approval for First-in-Human Phase 1 Trial in Gastrointestinal Cancers
GlycoNex receives PMDA approval to begin first-in-human Phase 1 trial of GNX1021 antibody-drug conjugate for advanced gastrointestinal cancers in Japan.
EMA AI System for Faster Drug Safety Signal Detection
The EMA's innovative AI system accelerates drug safety signal detection, ensuring timely responses to potential risks associated with medications.
European Commission Blockchain Pilot Enhances Pharmaceutical Supply Chain Security
The European Commission's blockchain pilot aims to bolster the security of the pharmaceutical supply chain, ensuring safer distribution of critical drugs like Xarelto.
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
The EMA has granted conditional approval for CAR-T therapy, offering new hope for patients with relapsed B-cell lymphoma.
EMA Issues Positive Opinion for Zepzelca (Lurbinectedin) in Cancer Treatment
European Medicines Agency delivers favorable assessment for lurbinectedin, marking significant regulatory milestone for advanced cancer therapy.
EMA Backs Amgen's Tarlatamab as First-in-Class BiTE Therapy for Advanced Small Cell Lung Cancer
European regulators issue positive opinion for tarlatamab (Imdylltra), marking potential breakthrough in extensive-stage SCLC treatment options.
EMA Issues Positive Opinion for Adstiladrin Gene Therapy in Bladder Cancer Treatment
European Medicines Agency recommends approval of nadofaragene firadenovec for high-risk non-muscle invasive bladder cancer patients.